Combination therapy of alpha-glucosidase inhibitor and a sulfonylurea compound prolongs the duration of good glycemic control

被引：16

作者：

Matsumoto, K ^{[1
]}

Sera, Y ^{[1
]}

Abe, Y ^{[1
]}

Tominaga, T ^{[1
]}

Ueki, Y ^{[1
]}

Miyake, S ^{[1
]}

机构：

[1] Sasebo Chuo Hosp, Dept Diabet & Metab Endocrinol & Rheumatol, Nagasaki 8571195, Japan

来源：

METABOLISM-CLINICAL AND EXPERIMENTAL | 2002年 / 51卷 / 12期

关键词：

D O I：

10.1053/meta.2002.36310

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The aim of this study was to investigate whether combination therapy of alpha-glucosidase inhibitor and a sulfonylurea (SU) drug can prolong the duration of good glycemic control compared with SU alone in patients with type 2 diabetes. The open prospective study included 124 Japanese patients with type 2 diabetes and inadequate glycemic control (hemoglobin A(1c) [HbA(1c)] gt; 7.0%). Patients were given either voglibose plus a SU compound (glibenclamide or gliclazide, n = 61) or SU drug alone (n = 63). The first 6-month run-in period (targeted to HbA(1c) less than or equal to 7.0%) was followed by treatment for 3 years. The endpoint was deterioration of glycemic control (HbA(1c) greater than or equal to 8.0%). Fifty patients on combination therapy and 48 patients on SU alone completed the trial. During the follow-up, 21 patients on combination therapy and 30 patients on SU alone showed deterioration of glycemic control and reached the endpoint (P = .04). The combination therapy significantly prolonged the duration of good glycemic control (HbA(1c) < 8.0%) compared with SU alone by Kaplan-Meier estimated survival analysis using a log-rank test (P = .02). Thus, combination therapy with voglibose and a SU agent prolongs the duration of good glycemic control compared with SU alone in patients with type 2 diabetes. Copyright 2002, Elsevier Science (USA). All rights reserved.

引用

页码：1548 / 1552

页数：5

共 22 条

[11] Acarbose in NIDDM patients with poor control on conventional oral agents - A 24-week placebo-controlled study [J].

Lam, KSL ;

Tiu, SC ;

Tsang, MW ;

Ip, TP ;

Tam, SCF .

DIABETES CARE, 1998, 21 (07) :1154-1158

[12] Glucose tolerance, insulin secretion, and insulin sensitivity in nonobese and obese Japanese subjects [J].

Matsumoto, K ;

Miyake, S ;

Yano, M ;

Ueki, Y ;

Yamaguchi, Y ;

Akazawa, S ;

Tominaga, Y .

DIABETES CARE, 1997, 20 (10) :1562-1568

[13] Effects of voglibose on glycemic excursions, insulin secretion, and insulin sensitivity in non-insulin-treated NIDDM patients [J].

Matsumoto, K ;

Yano, M ;

Miyake, S ;

Ueki, Y ;

Yamaguchi, Y ;

Akazawa, S ;

Tominaga, Y .

DIABETES CARE, 1998, 21 (02) :256-260

[14] The efficacy of voglibose on glycemic excursions in non-insulin-treated NIDDM patients -: Response -: Protection of the pancreatic β-cells by an α-glucosidase inhibitor [J].

Matsumoto, K ;

Yano, M ;

Ueki, Y ;

Miyake, S ;

Tominaga, Y .

DIABETES CARE, 1998, 21 (07) :1206-1207

[15] INSULIN-RESPONSE AFTER TREATMENT DEPENDS ON FASTING PLASMA-GLUCOSE LEVEL IN NIDDM [J].

MATSUMOTO, K ;

AKAZAWA, S ;

ABIRU, N ;

YANO, M ;

ISHIBASI, M ;

UOTANI, S ;

MATSUO, H ;

KAWASAKI, E ;

YAMASAKI, H ;

YAMAMOTO, H ;

YAMAGUCHI, Y ;

NAGATAKI, S .

DIABETES RESEARCH AND CLINICAL PRACTICE, 1994, 26 (02) :129-135

[16]

ROBERTSON P, 1992, DIABETOLOGIA S, V35, pS8

[17]

ROSSETTI L, 1990, DIABETES CARE, V18, P1156

[18] COUPLING OF BETA-CELL DESENSITIZATION BY HYPERGLYCEMIA TO EXCESSIVE STIMULATION AND CIRCULATING INSULIN IN GLUCOSE-INFUSED RATS [J].

SAKO, Y ;

GRILL, VE .

DIABETES, 1990, 39 (12) :1580-1583

[19] GLUCOSE EFFECTIVENESS IN 2 SUBTYPES WITHIN IMPAIRED GLUCOSE-TOLERANCE - A MINIMAL MODEL ANALYSIS [J].

TANIGUCHI, A ;

NAKAI, Y ;

DOI, K ;

FUKUSHIMA, M ;

NAGATA, I ;

KAWAMURA, H ;

IMURA, H ;

SUZUKI, M ;

TOKUYAMA, K .

DIABETES, 1994, 43 (10) :1211-1217

[20] PATHOGENIC FACTORS RESPONSIBLE FOR GLUCOSE-INTOLERANCE IN PATIENTS WITH NIDDM [J].

TANIGUCHI, A ;

NAKAI, Y ;

FUKUSHIMA, M ;

KAWAMURA, H ;

IMURA, H ;

NAGATA, I ;

TOKUYAMA, K .

DIABETES, 1992, 41 (12) :1540-1546

← 1 2 3 →